Jpmorgan Chase & CO Cara Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 34,040 shares of CARA stock, worth $8,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,040

Previous 31,157 9.25%

Holding current value

$8,850

Previous $23,000 30.43%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.52 - $1.05 $1,499 - $3,027	2,883 Added 9.25%	34,040 $30,000
Q4 2023 Feb 12, 2024	SELL	$0.6 - $1.65 $6,188 - $17,018	-10,314 Reduced 24.87%	31,157 $23,000
Q3 2023 Nov 14, 2023	BUY	$1.67 - $3.33 $641 - $1,278	384 Added 0.93%	41,471 $69,000
Q2 2023 Aug 11, 2023	SELL	$2.83 - $4.94 $99,349 - $173,423	-35,106 Reduced 46.08%	41,087 $116,000
Q1 2023 May 18, 2023	BUY	$4.89 - $12.27 $167,805 - $421,057	34,316 Added 81.94%	76,193 $374,000

Q1 2023 May 11, 2023	SELL	$4.89 - $12.27 $132,191 - $331,694	-27,033 Reduced 39.23%	41,877 $205,000
Q4 2022 Feb 13, 2023	SELL	$8.88 - $12.77 $2.49 Million - $3.58 Million	-279,965 Reduced 80.25%	68,910 $739,000
Q3 2022 Nov 14, 2022	SELL	$8.24 - $12.56 $80,521 - $122,736	-9,772 Reduced 2.72%	348,875 $3.27 Million
Q2 2022 Aug 11, 2022	BUY	$7.45 - $13.84 $442,753 - $822,511	59,430 Added 19.86%	358,647 $3.27 Million
Q1 2022 May 11, 2022	SELL	$9.94 - $12.65 $351,647 - $447,519	-35,377 Reduced 10.57%	299,217 $3.64 Million
Q4 2021 Feb 10, 2022	BUY	$11.99 - $18.14 $2.63 Million - $3.98 Million	219,470 Added 190.64%	334,594 $4.08 Million
Q3 2021 Nov 12, 2021	BUY	$11.55 - $16.06 $1.33 Million - $1.85 Million	115,124 New	115,124 $1.78 Million

Others Institutions Holding CARA

# of Institutions

102

Shares Held

21.5M

Call Options Held

50K

Put Options Held

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $14M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Cara Therapeutics, Inc. Transaction History